EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Clinical and Mechanistic Association Between Intestinal Permeability and the Gut Microbiome in Cirrhosis: Role of Phascolarctobacterium

Rosa Haller iD, Nicole Feldbacher, Stefan Fürst, Johannes Woltsche iD, Lukas Gulden, Jakob Schwarzl, Julia Traub, Tobias Madl iD, Hansjörg Habisch, Angela Horvath, Vanessa Stadlbauer

United European Gastroenterology Journal · 2026-07 · 14 (6)

DOI: 10.1002/ueg2.70262 ↗

Kurz gefasst

Fachartikel in der Zeitschrift United European Gastroenterology Journal, online erschienen am 13.07.2026. Verfasst von Rosa Haller und 10 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology and Hepatology, Department of Internal Medicine, Medical University of Graz, Graz, Austria. Hauptthemen laut MEDLINE: Liver Cirrhosis, Gastrointestinal Microbiome, Intestinal Mucosa. Die Arbeit nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Austrian Science Fund, Österreichische Forschungsförderungsgesellschaft, Integrative Metabolism Research Center Graz.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

In patients with liver cirrhosis, intestinal permeability and the composition of the gut microbiome are altered. Thus, the microbiome might be a therapeutic target for the treatment of both liver diseases and intestinal permeability. We aimed to investigate the relationship between the intestinal barrier and microbiome composition in cirrhosis and elucidate potential mechanisms for how bacteria influence permeability.

Methods

We analyzed the fecal permeability biomarker zonulin by ELISA and microbiome composition by 16s rDNA sequencing in a discovery ( n = 78) and a validation cohort ( n = 90) of patients with liver cirrhosis. In the validation cohort, we analyzed the composition of the fecal metabolome by NMR spectroscopy. For mechanistic exploration, an intestinal barrier cell culture model using T84 cells was used.

Results

In the discovery cohort ( n = 78, 77% Child‐Pugh Grade A, 21% Child‐Pugh Grade B, 3% Child‐Pugh Grade C), decreasing zonulin levels in stool over 6 months were associated with higher Phascolarctobacterium abundance in the microbiome. Phascolarctobacterium was associated with better liver function (lower bilirubin, p = 0.04, INR p = 0.04, MELD Score, p = 0.02). Lower Phascolarctobacterium levels were observed in decompensated cirrhosis and were associated with 36‐month mortality in two cohorts. Metabolomics analysis showed an association between Phascolarctobacterium and lower succinate levels. Succinate increased gut permeability in vitro, and Phascolarctobacterium succinatutens strains improved the intestinal permeability, potentially by alleviating the effect of succinate.

Conclusion

Phascolarctobacterium may represent a candidate biomarker of adverse outcomes in cirrhosis and a promising target for further investigation as a next‐generation probiotic involved in gut barrier function and succinate homeostasis. Trial Registration NCT01607528, NCT03080129

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Liver CirrhosisGastrointestinal MicrobiomeIntestinal MucosaHumansHaptoglobinsFecesIntestinal Barrier FunctionMaleProtein PrecursorsFemaleMiddle AgedPermeabilityCholera ToxinBiomarkersAgedMagnetic Resonance SpectroscopyRNA, Ribosomal, 16S

Stichwörter der Autor:innen

gut metabolomegut‐liver axisintestinal barriersuccinatezonulin

Substanzen

HaptoglobinszonulinProtein PrecursorsCholera ToxinBiomarkersRNA, Ribosomal, 16S

Autor:innen und Institutionen

  • Division of Gastroenterology and Hepatology, Department of Internal Medicine, Medical University of Graz, Graz, Austria.
  • Center for Biomarker Research in Medicine (CBmed), Graz, Austria.
  • Department of Clinical Medical Nutrition, University Hospital Graz, Graz, Austria.
  • Otto Loewi Research Center, Medicinal Chemistry, Medical University of Graz, Graz, Austria.
  • BioTechMed-Graz, Graz, Austria.

ORCID-Profile: Rosa Haller, Johannes Woltsche, Tobias Madl

Förderung

  • Austrian Science Fund
  • Österreichische Forschungsförderungsgesellschaft
  • Integrative Metabolism Research Center Graz
  • Austrian Infrastructure Program 2016/2017
  • Styrian Government; Zukunftsfonds; doc.fund program
  • City of Graz
  • BioTechMed-Graz
  • Doctoral program MOLMED

Zitieren

APA

Haller, R., Feldbacher, N., Fürst, S., Woltsche, J., Gulden, L., Schwarzl, J., Traub, J., Madl, T., Habisch, H., Horvath, A., & Stadlbauer, V. (2026). Clinical and Mechanistic Association Between Intestinal Permeability and the Gut Microbiome in Cirrhosis: Role of Phascolarctobacterium. United European Gastroenterology Journal, 14(6). https://doi.org/10.1002/ueg2.70262

Vancouver

Haller R, Feldbacher N, Fürst S, Woltsche J, Gulden L, Schwarzl J, et al. Clinical and Mechanistic Association Between Intestinal Permeability and the Gut Microbiome in Cirrhosis: Role of Phascolarctobacterium. United European Gastroenterology Journal. 2026;14(6). doi:10.1002/ueg2.70262

BibTeX
@article{Haller2026,
  author = {Haller, Rosa and Feldbacher, Nicole and Fürst, Stefan and Woltsche, Johannes and Gulden, Lukas and Schwarzl, Jakob and Traub, Julia and Madl, Tobias and Habisch, Hansjörg and Horvath, Angela and Stadlbauer, Vanessa},
  title = {Clinical and Mechanistic Association Between Intestinal Permeability and the Gut Microbiome in Cirrhosis: Role of Phascolarctobacterium},
  journal = {United European Gastroenterology Journal},
  year = {2026},
  volume = {14},
  number = {6},
  doi = {10.1002/ueg2.70262}
}
Kostenlos starten →